 Although further clinical experience is required before the relative place of acecainide in therapy can be determined, the drug nevertheless appears to offer advantages over procainamide, particularly with respect to the reduced formation of antinuclear antibodies.The dose of acecainide should be adjusted to control the patients’ arrhythmias and with regard to their clinical state including age, renal function and concurrent administration of other drugs.There appears to be an overlap in plasma concentrations required for therapeutic efficacy and those associated with adverse effects.